Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome Clinical Trial

Official title:

Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01890837
• Other study ID #: TU100CPT5
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 27, 2013
• Last updated: June 9, 2016
• Start date: August 2013
• Est. completion date: March 2015

Study information

• Verified date: June 2016
• Source: Tsumura USA
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Meet Rome III criteria for IBS.

2. Willing and able to provide written informed consent.

3. If a female of childbearing potential, must be using an acceptable form of contraception during the study and for 30 days after the last dose. Acceptable methods include surgical sterilization, hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing), condoms used with a spermicide, an IUD [Intrauterine device] or abstinence.

Females are not considered to be of childbearing potential if they are postmenopausal for at least 2 years or have been surgically sterilized.

4. Aged 18 to 65 years, inclusive.

5. Have a body mass index (BMI) between 18 and 40 kg/m2, inclusive.

6. Have a negative urine drug screening at Visit 1.

7. Have normal or not clinically significant laboratory results as reviewed by the study physicians.

8. Have a normal rectal examination result on file within the past 2 years or performed at Visit 1 in order to exclude the possibility of an evacuation disorder (examination must exclude findings suggestive of an evacuation disorder such as high sphincter tone at rest, failure of perineal descent and spasm, tenderness or paradoxical contraction of the puborectalis muscles).

9. Agree to avoid alcohol during the entire study to avoid corrupting the data from the rectal barostat tests.

Exclusion Criteria:

1. Have a structural or metabolic diseases or conditions that affect the GI system.

2. Be taking any medication that in the opinion of the principal investigator has a potential to alter GI transit (this includes but is not limited to osmotic or stimulant laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, gabapentin, pregabalin, narcotics, anticholinergics, antidepressants [including selective norepinephrine reuptake inhibitors], antipsychotics, opiates, GABAergic agents and benzodiazepines).

Note: Tricyclic antidepressants are permissible at doses equal to or less than 25 mg daily; selective serotonin reuptake inhibitor antidepressants are permissible at low, stable doses. Analgesics such as Tylenol, ibuprofen, naproxen and aspirin are not permissible during Visits 2 and 3 to avoid corrupting data from the rectal barostat tests. All medications will be reviewed by the principal investigator on a case by case basis.

Rescue medications: Rescue medications will be reviewed and approved as necessary for exacerbation of constipation or diarrhea since the study medication treatment period is about 14 days total. The patient will contact the study staff to request review and approval of the use of a rescue medication by the principal investigator. The use of the rescue medication will be documented by the patient in the bowel pattern, bloating and pain diary. Rescue medications are not allowed within 7 days of the rectal sensation studies to ensure data integrity.

3. Have clinical evidence, including but not limited to, of a clinically significant abnormal physical examination or laboratory value or of a past event documented in the past medical record, or current clinically significant abnormal physical examination or laboratory value that could indicate significant cardiovascular, respiratory, renal, hepatic, GI, hematological, neurological, psychiatric or other diseases that interfere with the objectives of the study. If a laboratory test value falls outside of the reference range and is considered clinically significant, it may be repeated once at the discretion of the principal investigator. If the laboratory test result remains abnormal and clinically significant, the patient will be discontinued from the study and referred to a primary care physician for evaluation.

4. Be a known substance abuser or be considered to be an alcoholic not in remission.

5. Have participated in another clinical study in the past 30 days.

6. Have a history of allergic reactions to egg, ginseng, ginger or Sichuan pepper.

7. Be clinically lactose intolerant.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abdominal Pain
• Digestive System Diseases
• Gastrointestinal Diseases
• Intestinal Diseases
• Irritable Bowel Syndrome
• Syndrome

Intervention

Drug:
• Daikenchuto (TU-100)
Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
• Placebo
Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

Locations

Country	Name	City	State
United States	Mayo Clinic, Rochester Methodist CRU	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Tsumura USA	Cato Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS		14 days	No
Primary	Sensation threshold for pain in response to distention of the rectum		14 days	No
Secondary	Rectal compliance at half-maximum pressure (Pr1/2)		14 days	No
Secondary	Rectal sensation thresholds (gas, urgency to defecate, first sensation)		14 days	No
Secondary	Rectal sensation ratings (pain, gas) in response to 32 mmHg distension of the rectum		14 days	No
Secondary	Rectal tone response to feeding 1,000 kcal meal		14 days	No
Secondary	Stool frequency		21 days	No
Secondary	Stool consistency as measured by the Bristol stool scale		21 days	No
Secondary	Daily average severity of abdominal pain on 100mm VAS		21 days	Yes
Secondary	Worst severity of abdominal pain each day measured on 100mm VAS scale		21 days	Yes
Secondary	Daily average severity of bloating on 100mm VAS scale		21 days	No
Secondary	IBS-QOL (Quality of Life) score		14 days	Yes
Secondary	Ease of bowel movements		21 days	No
Secondary	Completeness of evacuation		21 days	No